FDA accepted Tanabe Research Laboratories U.S.A. Inc.’s first Investigational New Drug application to initiate a phase I trial for its Antibody Drug Conjugate TR1801-ADC (MT- 8633) in patients with cMet positive solid tumors.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
